Novartis AG ADR (NVS)vsTscan Therapeutics Inc (TCRX)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
TCRX
Tscan Therapeutics Inc
$1.15
-8.73%
HEALTHCARE · Cap: $75.73M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 547871% more annual revenue ($56.58B vs $10.32M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
TCRX
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
-23.1%
Fair Value
$0.79
Current Price
$1.15
$0.36 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Revenue surging 286.0% year-over-year
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -71.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TCRX
The strongest argument for TCRX centers on Price/Book, Revenue Growth. Revenue growth of 286.0% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : TCRX
The primary concerns for TCRX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while TCRX is a hypergrowth play — different risk/reward profiles.
TCRX carries more volatility with a beta of 1.01 — expect wider price swings.
TCRX is growing revenue faster at 286.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 40/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Tscan Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tscan Therapeutics Inc (TCRX) is a clinical-stage biotechnology company committed to revolutionizing cancer treatment through its advanced T cell receptor (TCR) discovery platform, which targets specific cancer antigens for precision immunotherapy solutions. The firm’s innovative approach aims to translate cutting-edge scientific research into effective TCR-based therapeutics, enhancing treatment options for a variety of malignancies. With a robust pipeline and a solid intellectual property portfolio, Tscan Therapeutics is strategically positioned to become a key player in the fast-growing sector of T cell-based cancer therapies, addressing significant unmet medical needs and improving patient outcomes.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?